Biopharmaceutical company Attralus is directing attention to research presented this week at the annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) involving its AT-01 amyloid imaging agent.
In an oral presentation and posters, clinical data showed that AT-01 -- a radiolabeled, synthetic amyloid-targeted peptide designed for imaging of systemic amyloid deposits -- enabled detection of seven types of amyloid on PET/CT exams, according to Attralus. It also identified amyloid in anatomic sites not detected clinically, including presymptomatic cardiac amyloid, the company said.
AT-01 is currently being evaluated in a Phase 1/2 clinical trial in patients with a range of types of systemic amyloidosis, according to Attralus.
